Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and ...

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its own. It was approved in 2019 to treat severe depression.

Sanacora said that the Spravato efficacy data had to clear “a high bar” to win FDA approval. However, managing ...

Spravato should be used in conjunction with an oral antidepressant, according to both the FDA and Janssen. The FDA said this is the first time esketamine was approved for any use.

The FDA approval of Spravato comes after a controlled study showed the nasal spray provided rapid improvement in the ...

No, Spravato isn’t approved by the Food and Drug Administration (FDA) to treat anxiety or bipolar disorder. But in some cases, doctors may prescribe the drug off-label for these uses.

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression. ... Spravato was first approved back in 2019, but at that time, ...

Ketamine has been making headlines for years, from the death of actor Matthew Perry to Elon Musk's reported microdosing, to its portrayal in Hulu's "The Secret Lives of Mormon Wives." ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in people who have not responded to at least two oral antidepressants.

The FDA approval of Spravato comes after a controlled study showed the nasal spray provided rapid improvement in the Montgomery-Asberg Depression Rating Scale, when compared with a placebo.

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its own. It was approved in 2019 to treat severe depression.